Pneumocystis carinii Pneumonia Prophylaxis: Current Therapies and Recommendations

Journal of Pediatric Oncology Nursing

Volumn 28, Issue 3, 2011, Pages 179-184

  Crozier, Faith ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Pneumocystis jiroveci; pneumocystis pneumonia; prophylaxis

Indexed keywords

ANTIFUNGAL AGENT; ATOVAQUONE; COTRIMOXAZOLE; DAPSONE; PENTAMIDINE;

ARTICLE; HUMAN; INFANT; NEOPLASM; NURSING; OPPORTUNISTIC INFECTION; PNEUMOCYSTIS PNEUMONIA; PRACTICE GUIDELINE; RISK ASSESSMENT;

ANTIFUNGAL AGENTS; ATOVAQUONE; DAPSONE; HUMANS; INFANT; NEOPLASMS; OPPORTUNISTIC INFECTIONS; PENTAMIDINE; PNEUMONIA, PNEUMOCYSTIS; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 80053307856     PISSN: 10434542     EISSN: 15328457     Source Type: Journal    
DOI: 10.1177/1043454211408101     Document Type: Article

References (20)

1. Abidi M. H. Kozlowski J. R. Ibrahim R. B. Peres E. (2006). The sulfone syndrome secondary to Dapsone prophylaxis in a patient undergoing unrelated hematopoietic stem cell transplantation. Hematological Oncology, 24, 164-165.
2. Aviles R. Boyce T. G. Thompson D. M. (2004). Pneumocystis carinii pneumonia in a 3-month-old infant receiving high-dose corticosteroid therapy for airway hemangiomas. Mayo Clinic Proceedings, 79, 243-245.
3. Bachuss C. A. (2008). Glioblastoma multiforme: A case study. Internet Journal of Advanced Nursing Practice,9(2). Retrieved from http://www.ispub.com/journal/the_internet_journal_of_advanced_nursing_practice/volume_9_number_2_8/article/glioblastoma_multiforme_a_case_study.html
4. Bollée G. Sarfati C. Thiéry G. Bergeron A. de Miranda S. Menotti J… Azoulay E. (2007). Clinical picture of Pneumocystis jiroveci pneumonia in cancer patients. Chest, 132, 1305-1310.
5. Cotrimoxazole is generally used to manage Pneumocystis jiroveci pneumonia in children receiving chemotherapy. (2008). Drugs & Therapy Perspectives, 24(5), 9-12.
6. Green H. Paul M. Vidal L. Leibovici L. (2007a). Prophylaxis for pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database of Systematic Reviews, (3): CD005590. doi:10.1002/14651858.CD005590.pub2
7. Green H. Paul M. Vidal L. Leibovici L. (2007b). Prophylaxis of pneumocystis pneumonia in immunocompromised non-HIV-infected patients: Systematic review and meta-analysis of randomized controlled trials. Mayo Clinic Proceedings, 82, 1052-1059.
8. Kim S. Y. Dabb A. A. Glenn D. J. Snyder K. M. Chuk M. K. Loeb D. M. (2008). Intravenous pentamidine is effective as second line pneumocystis pneumonia prophylaxis in pediatric oncology patients. Pediatric Blood & Cancer, 50, 779-783. doi:10.1002/pbc.21287
9. Libecco J. A. Powell K. R. (2004). Trimethoprim/sulfamethoxazole: Clinical update. Pediatrics in Review/American Academy of Pediatrics, 25, 375-380.
10. Lindemulder S. Albano E. (2007). Successful intermittent prophylaxis with trimethoprim/sulfamethoxazole 2 days per week for Pneumocystis carinii (jiroveci) pneumonia in pediatric oncology patients. Pediatrics, 120, e47-51.
11. Madden R. M. Pui C. H. Hughes W. T. Flynn P. M. Leung W. (2007). Prophylaxis of Pneumocystis carinii pneumonia with Atovaquone in children with leukemia. Cancer, 109, 1654-1658. doi:10.1002/cncr.22562
12. Milligan K. S. Phillips D. L. (2007). Perioral numbness associated with intravenous Pentamidine administration. Annals of Pharmacotherapy, 41, 153-156.
13. Milstone A. M. Balakrishnan S. L. Foster C. B. Chen A. (2006). Failure of intravenous pentamidine prophylaxis to prevent pneumocystis pneumonia in a pediatric hematopoietic stem cell transplant (HSCT) patient. Pediatr Blood Cancer. 47, 859-860.
14. Ohata Y. Ohta H. Hashii Y. Tokimasa S. Ozono K. Hara J. (2009). Intermittent oral trimethoprim/sulfamethoxazole on two non-consecutive days per week is effective as Pneumocystis jiroveci pneumonia prophylaxis in pediatric patients receiving chemotherapy or hematopoietic stem cell transplantation. Pediatric Blood & Cancer, 52, 142-144. doi:10.1002/pbc.21774
15. Prasad P. Nania J. J. Shankar S. M. (2008). Pneumocystis pneumonia in children receiving chemotherapy. Pediatric Blood & Cancer, 50, 896-898. doi:10.1002/pbc.21202
16. Pyrgos V. Shoham S. Roilides E. Walsh T. J. (2009). Pneumocystis pneumonia in children. Paediatric Respiratory Reviews, 10, 192-198. doi:10.1016/j.prrv.2009.06.010
17. Sangiolo D. Storer B. Nash R. Corey L. Davis C. Flowers M… Boeckh M. (2005). Toxicity and efficacy of daily dapsone as Pneumocystis jiroveci prophylaxis after hematopoietic stem cell transplantation: A case-control study. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation, 11, 521-529. doi:10.1016/j.bbmt.2005.04.011
18. Shankar S. M. Nania J. J. (2007). Management of Pneumocystis jiroveci pneumonia in children receiving chemotherapy. Paediatric Drugs, 9, 301-309.
19. Suryaprasad A. Stone J. H. (2008). When is it safe to stop Pneumocystis jiroveci pneumonia prophylaxis? Insights from three cases complicating autoimmune diseases. Arthritis & Rheumatism, 59, 1034-1039.
20. Williams S. MacDonald P. Hoyer J. D. Barr R. D. Athale U. H. (2005). Methemoglobinemia in children with acute lymphoblastic leukemia (ALL) receiving dapsone for Pneumocystis carinii pneumonia (PCP) prophylaxis: A correlation with cytochrome b5 reductase (Cb5R) enzyme levels. Pediatric Blood & Cancer, 44, 55-62. doi:10.1002/pbc.20164